Free Trial

This company has been marked as potentially delisted and may not be actively trading.

BeiGene (BGNE) News Today

BeiGene logo
BeiGene gewinnt Patentstreit gegen Pharmacyclics
BeiGene reports financial results under PRC GAAP
BeiGene announces FDA approval of Tevimbra/chemotherapy combination
BeiGene Announces FDA Approval Of TEVIMBRA - Quick Facts
BeiGene announces FDA approval of Tevimbra
BeiGene, Ltd. stock logo
BeiGene, Ltd. (NASDAQ:BGNE) Receives Average Recommendation of "Moderate Buy" from Analysts
BeiGene, Ltd. (NASDAQ:BGNE - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight research firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and six have assigned a buy r
BeiGene (BGNE) Gets a Buy from TD Cowen
Get BeiGene News Delivered to You Automatically

Sign up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.

BGNE Media Mentions By Week

BGNE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BGNE
News Sentiment

0.00

0.73

Average
Medical
News Sentiment

BGNE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BGNE Articles
This Week

5

5

BGNE Articles
Average Week

Get BeiGene News Delivered to You Automatically

Sign up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:BGNE) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners